Alba E et al; Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004;22(13):2587-93. Abstract

Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.

Bari M et al. Capecitabin (C) plus weekly paclitaxel (wP) in metastatic breast cancer (MBC). A phase II study. Proc ASCO 2003;Abstract 262.

Bernard-Marty C et al. Use and abuse of taxanes in the management of metastatic breast cancer. Eur J Cancer 2003;39(14):1978-89. Abstract

Biganzoli L et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002;20(14):3114-21. Abstract

Blohmer JU et al. Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin– cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 627.

Blum JL et al. ABI-007 nanoparticle paclitaxel: Demonstration of anti-tumor activity in taxanerefractory metastatic breast cancer. Proc ASCO 2003;Abstract 64.

Bottomley A et al; European Organization for Research and Treatment of Cancer Breast Cancer Group. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 2004;22(13):2576-86. Abstract

Bria E et al. Impact of taxanes in association with anthracyclines in 1st line chemotherapy for metastatic breast cancer (MBC): Comprehensive review of 2805 patients in 7 phase III trials. Proc ASCO 2004;Abstract 659.

Chun JH et al. Frontline docetaxel (T)/ capecitabine (X) combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study. Proc ASCO 2004;Abstract 778.

Clemons MJ et al. Palliative chemotherapy with vinorelbine or capecitabine in women with anthracycline and taxane refractory metastatic breast cancer. Proc ASCO 2004;Abstract 773.

Cresta S et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 2004;15(3):433-9. Abstract

Crown J, Pegram M. Platinum-taxane combinations in metastatic breast cancer: An evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 2003;79(Suppl 1):11-8. Abstract

Estevez LG et al. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Proc ASCO 2004;Abstract 748.

Freyer G et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003;21(1):35-40. Abstract

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003;64(3):191-206. Abstract

Jones S et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2003;Abstract 10.

Lago S et al. Quality of life (QoL) in metastatic breast cancer (MBC) patients taking capecitabine. Proc ASCO 2003;Abstract 2994.

Longo F et al. Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 839.

Minea LN et al. Capecitabine monotherapy for elderly patients with metastatic breast cancer. Proc ASCO 2004;Abstract 797.

Moinpour C et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. Proc ASCO 2004;Abstract 621.

Nabholtz JM. Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat 2003;79(Suppl 1):3-9. Abstract

Nabholtz JM et al; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21(6):968-75. Abstract

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

O’Shaughnessy JA et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract

Paridaens R et al. A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann Oncol 2003;14(3):433-40. Abstract

Parnes HL et al; Cancer and Leukemia Group B. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol 2003;21(9):1819-24. Abstract

Perez EA et al. A randomized phase II study of sequential docetaxel and doxorubicin/
cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 2002;13(8):1225-35. Abstract

Rossi A et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 2003;23(2C):1657- 64. Abstract

Segalla JGM et al. Effect of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 8130.

Seidman AD. Monotherapy options in the management of metastatic breast cancer. Semin Oncol 2003;30(2 Suppl 3):6-10. Abstract

Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.

Seidman AD et al. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002;7(Suppl 6):20-8. Abstract

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract

Talbot DC et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract

Winer EP et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol 2004;22(11):2061-8. Abstract